<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cardiac and vascular disease in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cardiac and vascular disease in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cardiac and vascular disease in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melvin D Cheitlin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajesh T Gandhi, MD, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac abnormalities were appreciated early in the epidemic of acquired immunodeficiency syndrome (AIDS), even before the etiologic agent, human immunodeficiency virus (HIV), was isolated and characterized. Decades later, the etiology and pathogenesis of myocarditis and cardiomyopathy associated with HIV infection remain a subject of intense speculation [
         <a href="#rid1">
          1,2
         </a>
         ]. In the era of potent antiretroviral therapy (ART), patients are living longer, and the disease has become a chronic infection, even in low- and middle-income countries [
         <a href="#rid3">
          3
         </a>
         ]. Nevertheless, HIV infection is associated with increased mortality [
         <a href="#rid4">
          4
         </a>
         ], and a growing body of evidence implicates chronic inflammation that persists despite effective ART in the development of vascular dysfunction and accelerated atherosclerosis [
         <a href="#rid5">
          5
         </a>
         ]. There is also evidence that HIV and possibly ART produce myocardial dysfunction by inflammatory cytokine release that results in myocardial fibrosis, apoptosis, and cardiac steatosis [
         <a href="#rid6">
          6
         </a>
         ]. Atherosclerotic vascular disease, especially coronary artery disease, has become the most important cardiovascular complication of HIV infection and has had the most attention directed to its pathogenesis, prevention, and therapy [
         <a href="#rid7">
          7,8
         </a>
         ]. In some resource-limited settings where medical treatment is sparse, limited, or absent, HIV disease and its complications are similar to the disease in the pre-ART era [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         This topic is devoted to the spectrum of cardiac and vascular diseases seen in patients with HIV. Discussions related specifically to coronary artery disease and its management in patients with HIV are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83686.html" rel="external">
          "Pathogenesis and biomarkers of cardiovascular disease in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TYPES OF CARDIAC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV infection can have a variety of cardiac and vascular manifestations. However, certain cardiac disorders have been reported with greater frequency among patients with HIV compared with the general population; the specific type of cardiac disease varies by setting.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular/coronary artery disease
         </strong>
         – In resource-rich countries, with the widespread availability of potent antiretroviral therapy (ART), patients are living longer, and other comorbidities have surfaced, such as hypertension, metabolic abnormalities (hyperglycemia, hyperlipidemia, lipodystrophy), and accelerated atherosclerosis, including coronary artery disease [
         <a href="#rid7">
          7,9-13
         </a>
         ]. Thus, cardiovascular disease has emerged as a major cause of morbidity and mortality in patients with HIV. As an example, in a study from the United States of death certificates that listed HIV infection, the proportion of deaths attributed to heart disease increased from 5 to 10 percent from 1996 to 2006 [
         <a href="#rid14">
          14
         </a>
         ]. Although cardiovascular disease is accounting for a larger percentage of all those who died, the number of patients dying from cardiovascular disease has actually decreased. In a study of almost 50,000 patients with HIV, all-cause deaths decreased by 48 percent from 17.5 deaths per 1000 person-years in 1999 to 2000 to 9.1 deaths per 1000 person-years in 2009 to 2011; cardiovascular deaths also decreased by 50 percent over this time period from 1.8 to 0.9 deaths per 1000 person-years [
         <a href="#rid15">
          15
         </a>
         ]. Of all mortality related to HIV infection, only 6.5 percent is attributable to cardiovascular disease [
         <a href="#rid16">
          16
         </a>
         ]. The decrease in cardiovascular death could be explained by improved use of non-HIV-specific cardiovascular disease preventive measures. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart failure
         </strong>
         – HIV infection has been associated with an increased risk of heart failure in the ART era [
         <a href="#rid17">
          17,18
         </a>
         ]. In the Veterans Aging Cohort Study, which followed 98,015 patients without baseline cardiovascular disease for a median of 7.1 years, veterans with HIV had an increased risk of heart failure with reduced ejection fraction (HFrEF; hazard ratio [HR] 1.61, 95% CI 1.40-1.86) and heart failure with preserved (HFpEF; HR 1.37, 95% CI 1.09-1.72) compared with matched seronegative veterans [
         <a href="#rid17">
          17
         </a>
         ]. The risk of HFrEF was associated with high HIV viral loads (&gt;500 copies/mL) and low CD4 cell counts (&lt;200/microL), and it was pronounced in veterans younger than 40 years at baseline (HR 3.59, 95% CI 1.95-6.58).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial and myocardial disease
         </strong>
         – By contrast, pericardial effusion and myocardial disease, such as myocarditis and cardiomyopathy, which were frequently reported among patients with HIV before the widespread use of ART, particularly in the setting of significant immunosuppression, are increasingly uncommon. However, in resource-limited settings, where some patients have limited access to ART, these syndromes remain common manifestations of HIV-associated cardiac disease [
         <a href="#rid19">
          19,20
         </a>
         ]. In a study of 5328 patients presenting with a first diagnosis of heart disease to a large cardiology center in South Africa, 518 (10 percent) had HIV, among whom cardiomyopathy was diagnosed in 38 percent and pericarditis in 13 percent [
         <a href="#rid20">
          20
         </a>
         ]. Only 14 patients with HIV (2.7 percent) had a diagnosis of coronary artery disease. This pattern may change as the use of ART worldwide has been increasing. (See
         <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">
          "Global epidemiology of HIV infection", section on 'ART coverage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         – Pulmonary arterial hypertension is a relatively uncommon vascular complication associated with HIV infection. It can occur at all stages of infection, does not seem to be related to the degree of immunodeficiency, and carries a poor prognosis. (See
         <a class="medical medical_review" href="/z/d/html/8246.html" rel="external">
          "Pulmonary arterial hypertension associated with human immunodeficiency virus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other cardiac and vascular processes that have been associated with HIV infection include venous thromboembolic disease, peripheral artery disease (PAD), infective endocarditis (mainly in people who inject drugs), cardiac rhythm disturbances, and very rarely, cardiac tumors.
        </p>
        <p class="headingAnchor" id="H568654047">
         <span class="h1">
          CARDIOVASCULAR DISEASE AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In resource-rich settings, where there is widespread availability of potent antiretroviral therapy (ART), cardiovascular disease has emerged as an important cause of death in patients with HIV relative to the decreasing incidence of opportunistic disease. Several lines of evidence, from modeling of calculated cardiovascular risk to clinical studies evaluating such hard endpoints as stroke, myocardial infarctions, and sudden cardiac death, have cumulatively supported this finding. The epidemiology, pathogenesis, and management of cardiovascular disease and risk factors in patients with HIV are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83686.html" rel="external">
          "Pathogenesis and biomarkers of cardiovascular disease in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          MYOCARDIAL DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H347005872">
         <span class="h2">
          Clinical findings and prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the prevalence of HIV-associated myocardial disease has dropped significantly in resource-rich areas since the widespread use of antiretroviral therapy (ART), subtle abnormalities in myocardial structure and function on echocardiography and imaging are still observed among treated individuals with HIV. Cardiomyopathy associated with HIV infection remains a major issue in resource-limited settings.
        </p>
        <p>
         The spectrum of myocardial disease in patients with HIV infection ranges from incidental asymptomatic findings to symptomatic heart failure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal myocarditis, usually seen incidentally at autopsy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of abnormal myocardial structure or function on cardiovascular imaging
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical cardiomyopathy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H519455145">
         <span class="h3">
          Focal myocarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In autopsy studies performed before the widespread availability and use of ART, myocarditis was detected among 9 to 52 percent of patients with HIV (average 33 percent) [
         <a href="#rid21">
          21-23
         </a>
         ]. Nearly all had focal collections of mononuclear cells with or without evidence of myocardial necrosis, and ventricular dilatation was occasionally seen [
         <a href="#rid22">
          22
         </a>
         ]. Most of these patients had had no cardiovascular signs or symptoms [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         There are minimal data on the prevalence of histopathological myocarditis among individuals with HIV in the ART era; however, advanced imaging studies suggest that subtle findings potentially reflective of prior myocarditis are still evident in patients with HIV on ART. In a study from the United Kingdom of 90 patients with HIV taking ART with a mean CD4 cell count of 546 cells/microL and without a known history of cardiac disease or associated symptoms, 76 percent had evidence by cardiac magnetic resonance imaging (MRI) of patchy myocardial fibrosis, possibly suggestive of prior myocarditis, compared with 13 percent among 39 age- and ethnicity-matched controls without HIV [
         <a href="#rid25">
          25
         </a>
         ]. Despite the increased frequency in myocardial fibrosis among patients with HIV overall, the actual volume of focal fibrosis in each individual remained low in both groups. The overall burden of left ventricular patchy fibrosis was small: 4 percent in the cohort with HIV and 2 percent in the control subjects. An endomyocardial biopsy study from South Africa conducted in the ART era found histologic evidence of myocarditis in 44 percent of 14 patients with HIV-associated cardiomyopathy compared with 25 percent of patients with idiopathic cardiomyopathy [
         <a href="#rid26">
          26
         </a>
         ]. Infection with a cardiotropic virus (eg, Epstein-Barr virus, herpes simplex virus, etc) was present in 100 percent of HIV-associated cardiomyopathy and in 90 percent of idiopathic dilated cardiomyopathy patients. Patients with HIV-associated cardiomyopathy had a mean of 2.5 cardiotropic viruses identified.
        </p>
        <p class="headingAnchor" id="H784418106">
         <span class="h3">
          Abnormalities on cardiovascular imaging
         </span>
        </p>
        <p class="headingAnchor" id="H519455153">
         <span class="h4">
          Echocardiographic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several asymptomatic echocardiographic abnormalities have been reported among patients with HIV at various disease stages. In particular, left ventricular diastolic dysfunction appears to be the most common finding; with the more widespread use of ART, the presentation of HIV cardiomyopathy has evolved from clinically severe cardiac systolic dysfunction to a pattern of subclinical cardiac dysfunction manifest by abnormal diastolic function and strain [
         <a href="#rid27">
          27
         </a>
         ]. Nevertheless, systolic dysfunction is also observed with moderate frequency, particularly among untreated patients with HIV.
        </p>
        <p>
         Among patients with HIV who have access to ART, subclinical structural and functional cardiac abnormalities are found more frequently compared with the general population and appear to be associated with cardiovascular and metabolic risk factors [
         <a href="#rid28">
          28-33
         </a>
         ]. As an example, in a study of 196 adults with HIV in the United States, 97 (49 percent) had echocardiographic evidence of diastolic dysfunction compared with 15 (29 percent) of 52 age- and gender-matched controls [
         <a href="#rid30">
          30
         </a>
         ]. Among patients with HIV, the presence of diastolic dysfunction was not independently associated with CD4 cell count, HIV ribonucleic acid (RNA) level, or duration of ART after adjustment for age and hypertension. Only 4 percent of patients with HIV and no controls had systolic dysfunction (ejection fraction &lt;50 percent). In a meta-analysis of 11 studies from the ART era including over 2000 patients with HIV, the prevalence of diastolic and systolic dysfunction by echocardiography was 43.4 and 8.3 percent, respectively [
         <a href="#rid33">
          33
         </a>
         ]. Hypertension and older age were independently associated with diastolic dysfunction, and a history of myocardial infarction, an elevated C-reactive protein level, and current tobacco smoking were independently associated with systolic dysfunction.
        </p>
        <p>
         By contrast, in resource-limited settings, echocardiographic abnormalities associated with HIV, in particular left ventricular systolic dysfunction, are generally associated with immunosuppression [
         <a href="#rid34">
          34,35
         </a>
         ]. As an example, in a study from Rwanda that included 416 untreated patients with HIV and without known cardiac disease, left ventricular dilatation and dysfunction (ejection fraction &lt;45 percent) was found in 71 (18 percent) [
         <a href="#rid34">
          34
         </a>
         ]. On multivariate analysis, low socioeconomic status, longer duration of HIV infection, higher HIV viral load, more advanced HIV stage, and low
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          selenium
         </a>
         plasma level were factors significantly associated with the presence of systolic dysfunction.
        </p>
        <p class="headingAnchor" id="H614939281">
         <span class="h4">
          Magnetic resonance abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac MRI can also identify more subtle and subclinical myocardial abnormalities. Several studies have suggested that individuals with HIV have a higher rate of MRI findings suggestive of myocardial inflammation and fibrosis [
         <a href="#rid25">
          25,36,37
         </a>
         ].
        </p>
        <p>
         As an example, a cross-sectional study of 90 individuals with HIV reported a 47 percent greater myocardial lipid content on proton magnetic resonance spectroscopy compared with matched controls [
         <a href="#rid25">
          25
         </a>
         ]. In this study, subjects with HIV had lower median high-density lipoprotein cholesterol, higher total cholesterol/high-density lipoprotein ratio, and higher plasma triglycerides than subjects without HIV.
        </p>
        <p>
         Other MRI findings are generally consistent with those of echocardiographic findings associated with HIV infection [
         <a href="#rid25">
          25,37
         </a>
         ] (see
         <a class="local">
          'Echocardiographic abnormalities'
         </a>
         above). In a study of 103 patients with HIV without known cardiovascular disease on ART, MRI demonstrated lower left ventricle ejection fraction, higher left ventricle mass, and lower peak diastolic strain rates compared with 92 uninfected controls [
         <a href="#rid37">
          37
         </a>
         ]. Small pericardial effusions and myocardial fibrosis were three and four times more common in the patients with HIV infection. Chronic systemic inflammation affecting the pericardium and myocardium may explain these findings.
         <strong>
         </strong>
        </p>
        <p class="headingAnchor" id="H519455219">
         <span class="h3">
          Symptomatic cardiomyopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically symptomatic cardiomyopathy is less common than histopathologic and cardiovascular imaging abnormalities, even in the era prior to the availability of potent ART, when it was reported in approximately 1 to 3 percent of patients with AIDS and the incidence of new cases was 1 to 2 percent [
         <a href="#rid38">
          38-41
         </a>
         ]. Nevertheless, it remains a significant manifestation of cardiac disease among individuals with HIV in resource-limited settings.
        </p>
        <p>
         In a study from South Africa of patients presenting with newly diagnosed heart disease, among the 518 patients with HIV included, cardiomyopathy (left ventricular dysfunction or dilatation) was the most common primary diagnosis, made in 38 percent, and the majority (86 percent) of these patients reported some level of symptoms and functional limitation [
         <a href="#rid20">
          20
         </a>
         ]. By contrast, among the total cohort of 5328 patients, cardiomyopathy was only documented in 3.7 percent.
        </p>
        <p>
         The clinical presentation of cardiomyopathy is similar in patients with HIV as in those who are not infected. The initial symptoms are nonspecific: as an example, dyspnea may be due to pulmonary involvement or cardiac disease. More specific signs of cardiac involvement are an S3 gallop or pulmonary edema or a pathologic murmur. The clinical presentation of heart failure is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H347005178">
         <span class="h2">
          Etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathophysiology of HIV cardiomyopathy is unclear but is probably multifactorial. Some patients with asymptomatic or overt left ventricular dysfunction have a known or clear etiology such as coronary artery disease, cocaine use, alcoholic heart disease, drug toxicity, or myocarditis due to an opportunistic infection such as toxoplasmosis or cryptococcosis [
         <a href="#rid1">
          1,2,42
         </a>
         ]. The endothelium is a reservoir for HIV and produces cytokines such as tumor necrosis factor, interleukin-6, and free radicals in response to inflammation that in turn causes myocardial dysfunction. Direct infection of myocardial cells by HIV, while possible, is controversial, since cardiac myocytes lack HIV receptors [
         <a href="#rid43">
          43
         </a>
         ]. Other possible causes of myocardial dysfunction include mitochondrial damage from certain antiretroviral agents, such as nucleoside reverse transcriptase inhibitors (NRTIs) [
         <a href="#rid43">
          43
         </a>
         ]. These possible etiologies are discussed in detail below.
        </p>
        <p>
         However, in a number of cases, the etiology and pathogenesis is unknown or unidentified.
        </p>
        <p>
         The etiology of heart failure and myocarditis in general is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">
          "Causes of dilated cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4933.html" rel="external">
          "Myocarditis: Causes and pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H568654094">
         <span class="h3">
          Cardiac ischemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the increasing prevalence of cardiovascular disease among individuals with HIV in resource-rich settings, cardiac ischemia has emerged as an important cause of clinical or subclinical cardiomyopathy in this population [
         <a href="#rid43">
          43-45
         </a>
         ]. The etiology of vascular disease in patients with HIV is multifactorial and includes an increased prevalence of traditional coronary disease risk factors, dyslipidemia with certain antiretrovirals, insulin resistance, and endothelial dysfunction. The role of chronic inflammation and immune activation may be central to the increased risk of coronary artery disease [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         .)
        </p>
        <p>
         In a study of 608 patients with HIV hospitalized for an acute myocardial infarction in France, the prevalence of ischemic cardiomyopathy was higher compared with 1216 uninfected controls matched for age and gender (7.6 versus 4.2 percent) [
         <a href="#rid46">
          46
         </a>
         ]. Although in-hospital and one-year mortality rates were similar in both groups, patients with HIV were more likely to be rehospitalized for heart failure during that year than the controls (3.3 versus 1.4 percent).
        </p>
        <p class="headingAnchor" id="H568654087">
         <span class="h3">
          Myocarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although an alternative causative pathogen can be identified in some cases of myocarditis in patients with HIV, the etiology of 80 to 85 percent of cases remain uncertain. Direct invasion by HIV itself may be responsible, but this is controversial. Although HIV has been identified in myocardial biopsies from patients with HIV cardiomyopathy [
         <a href="#rid47">
          47
         </a>
         ], the virus may have been in blood or endothelial cells rather than in myocardial cells. Other cardiotropic viruses that are not directly identified, such as cytomegalovirus, coxsackievirus, or Epstein-Barr virus, also may be important [
         <a href="#rid7">
          7,26,42
         </a>
         ]. Additionally, a dysregulated inflammatory process induced by HIV or other cardiotropic viruses may also contribute.
        </p>
        <p class="headingAnchor" id="H347005184">
         <span class="h4">
          Coinfections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with myocarditis, opportunistic bacterial, fungal, and protozoan pathogens can be identified in approximately 10 to 15 percent of cases [
         <a href="#rid7">
          7,26,42
         </a>
         ]. Other cardiotropic viruses may also contribute to cardiomyopathy in patients with HIV.
        </p>
        <p>
         In a South African study in which 14 patients with HIV-associated cardiomyopathy underwent endomyocardial biopsy, myocarditis was identified in 44 percent, and a cardiotropic virus was identified in all [
         <a href="#rid26">
          26
         </a>
         ]. The most common were Epstein-Barr virus, herpes simplex virus, and HIV.
        </p>
        <p>
         Other infectious etiologies that have been implicated in dilated cardiomyopathy associated with HIV infection include coxsackievirus [
         <a href="#rid23">
          23,41,48
         </a>
         ], cytomegalovirus [
         <a href="#rid23">
          23,41,49
         </a>
         ], and
         <em>
          Cryptococcus neoformans
         </em>
         [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         One autopsy series published in 1993 found 12 percent of 182 patients with HIV had cardiac toxoplasmosis [
         <a href="#rid51">
          51
         </a>
         ]. However, symptomatic disease appears to be rare. A French survey estimated the prevalence of clinical extracerebral toxoplasmosis among individuals with HIV presenting to care at 1.5 to 2 percent; only 3 percent of these patients had cardiac disease [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H347005190">
         <span class="h4">
          Role of direct HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether direct infection of the heart by HIV contributes to development of myocarditis in patients with end-stage HIV disease is unclear, but some studies suggest that it is possible. Since the myocardial cell lacks CD4 receptors, HIV is denied the usual mode of entrance into the cell. However, the organism could enter the cell if the cell was injured by another virus. In in vitro studies, for example, Epstein-Barr virus permitted the entrance and replication of HIV into CD4 receptor-negative myocardial cells [
         <a href="#rid53">
          53
         </a>
         ]. In addition, HIV has been localized in or near the myocardial cell by immunocytochemical techniques [
         <a href="#rid54">
          54-56
         </a>
         ] and in situ deoxyribonucleic acid (DNA) hybridization [
         <a href="#rid23">
          23,57,58
         </a>
         ]. In one study, HIV was seen in 25 percent of samples by in situ hybridization, albeit in low signal level [
         <a href="#rid57">
          57
         </a>
         ]. However, HIV sequences also can be identified in patients with HIV and without apparent cardiac disease.
        </p>
        <p>
         HIV may also cause indirect damage through inflammation, production of free radicals, and increased susceptibility to infections, toxins, and ischemia [
         <a href="#rid43">
          43
         </a>
         ]. Endothelial cells can act as a reservoir for HIV as well as produce cytokines, such as tumor necrosis factor (TNF) and interleukin (IL)-6.
        </p>
        <p>
         Evidence from studies of simian immunodeficiency virus (SIV)-infected primates supports retroviral infection of cells other than myocytes, mainly monocytes, as being the major cell type in inflammatory heart disease in the simian model [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H347005390">
         <span class="h4">
          Altered immune response
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dysregulated immune function observed in the setting of HIV infection has been hypothesized to contribute to myocardial dysfunction. Cytokines, such as TNF-alpha, IL-1, IL-2, endothelin (ET)-1, and alpha interferon [
         <a href="#rid60">
          60-62
         </a>
         ] are proteins or large peptides released by HIV-infected macrophages. These cytokines increase the production of inducible nitric oxide synthase (iNOS) and nitric oxide, which are cytotoxic to myocardial cells; furthermore, TNF and reactive oxygen species may signal the onset of myocyte apoptosis leading to progressive loss of ventricular function [
         <a href="#rid56">
          56,63-65
         </a>
         ]. Enhanced expression of iNOS is seen particularly in patients with low CD4 cell counts [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4933.html" rel="external">
          "Myocarditis: Causes and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">
          "Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Nitric oxide'
         </a>
         .)
        </p>
        <p>
         The immune reconstitution inflammatory syndrome (IRIS), a pathologic inflammatory response associated with the rapid recovery of the immune system, has also been implicated in the development of acute myocarditis [
         <a href="#rid67">
          67
         </a>
         ]. Similarly, autoimmune disease, which can surface when immune competence is restored with introduction of ART, may contribute to myocardial dysfunction [
         <a href="#rid68">
          68,69
         </a>
         ]. Cardiotropic viruses have the potential to alter cell surface antigens, leading to an autoimmune reaction to endogenous epitopes; cardiac-specific autoantibodies are more commonly found among patients with HIV infection than patients without [
         <a href="#rid43">
          43
         </a>
         ]. HIV-associated polyclonal B-cell stimulation could also be related to the formation of autoantibodies.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Cardiotoxic agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alcohol and other substances
         </strong>
         – Alcohol, cocaine, and methamphetamine have all been associated with the development of cardiomyopathy. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3467.html" rel="external">
          "Alcohol-induced cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4953.html" rel="external">
          "Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse", section on 'Cardiomyopathy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14839.html" rel="external">
          "Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis", section on 'Cardiovascular disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Concomitant methamphetamine use and HIV infection enhances immunosuppression and increases the risk of cardiac complications [
         <a href="#rid70">
          70
         </a>
         ]. Methamphetamines have been shown to significantly increase HIV reverse transcriptase activity in human monocyte-derived macrophages by upregulating the expression of the HIV entry coreceptor CCR5 on macrophages. In this way, methamphetamines function as a cofactor in the immunopathogenesis of HIV infection [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic agents
         </strong>
         – Cardiotoxicity from therapeutic drugs such as
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         [
         <a href="#rid72">
          72
         </a>
         ] and possibly
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         [
         <a href="#rid73">
          73
         </a>
         ] may contribute to the development of cardiomyopathy in patients with HIV. Zidovudine produces cardiomyopathy in mice with pathologic changes in the mitochondria [
         <a href="#rid1">
          1,74
         </a>
         ]. Patients with HIV and cardiomyopathy have been reported on myocardial biopsy to have similar ultrastructural changes in their mitochondria. In one case, reversal of the cardiac dysfunction was seen on discontinuation of the zidovudine therapy [
         <a href="#rid75">
          75
         </a>
         ]. However, zidovudine is rarely used given the availability of less toxic antiretroviral agents.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H347005729">
         <span class="h3">
          Nutritional factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some studies have suggested that nutritional issues such as general cachexia or
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          selenium
         </a>
         deficiency may play a role in HIV-associated cardiomyopathy [
         <a href="#rid34">
          34,41,76,77
         </a>
         ], although there is no convincing direct evidence of this. In one report of eight patients with HIV-associated cardiomyopathy, six had a deficiency of selenium [
         <a href="#rid77">
          77
         </a>
         ]. Of the three patients who received selenium supplementation, two had clinical and electrocardiographic improvement after selenium levels normalized; the third had no improvement.
        </p>
        <p class="headingAnchor" id="H347005920">
         <span class="h2">
          Diagnosis and evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of cardiomyopathy in patients with HIV, as in the general population, is made through the finding of characteristic abnormalities on electrocardiography, chest radiograph, and echocardiography in the setting of symptoms and signs suggestive of heart failure. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         Routine echocardiography in asymptomatic patients with HIV is not indicated, as there appears to be no advantage to finding subclinical disease, except for possibly motivating more rigorous control of vascular risk factors, which may be warranted even in the absence of asymptomatic cardiomyopathy. Although echocardiography can detect diastolic dysfunction in an asymptomatic patient with HIV, apart from treating diseases that can precipitate or worsen the ventricular dysfunction, such as hypertension or coronary artery disease, there is no evidence that there is any therapy that can improve diastolic dysfunction.
        </p>
        <p>
         Further evaluation of patients with HIV and symptomatic cardiomyopathy is similar to that for the general population, which includes an assessment for cardiovascular risk factors, underlying coronary artery disease, and use of potentially cardiotoxic agents (alcohol, illicit substances, or therapeutic drugs). Additionally, because of the potential of certain opportunistic infections to cause myocarditis, patients with significant immunosuppression (ie, CD4 cell count &lt;200 cells/microL) should also be tested for
         <em>
          Toxoplasma
         </em>
         serology and
         <em>
          Cryptococcus neoformans
         </em>
         serum antigen. (See
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         Certain biomarkers may be useful in predicting myocardial dysfunction and outcomes in patients with HIV, but evidence supporting them is limited and most are not clinically available. In a study of 332 patients with HIV and 50 age- and sex-matched controls, the stress-related biomarkers ST2 and growth differentiation factor-15 were associated with cardiovascular dysfunction and all-cause mortality in ambulatory patients with HIV [
         <a href="#rid78">
          78
         </a>
         ]. However, the rate of systolic dysfunction in this study was low, with a left ventricular ejection fraction &lt;50 percent in only 5 percent. There were 38 deaths in the patients with HIV in a median of 6.1 years.
        </p>
        <p>
         The utility of myocardial biopsy is controversial, as the identification of a treatable etiology of myocarditis is rare. The indications for myocardial biopsy in general are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">
          "Endomyocardial biopsy", section on 'Indications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H347005973">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of the patient with HIV and symptomatic cardiomyopathy is similar to that in the general population, which is discussed in detail elsewhere. There are limited data on the efficacy of these interventions in the setting of HIV infection, so the efficacy is extrapolated from evidence in the general population. (See
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p>
         Correction of any identified underlying cause of the cardiomyopathy is warranted. As an example, drugs that have been implicated in cardiomyopathy should be discontinued. Additionally, with increasing evidence that patients with HIV, especially those on ART regimens, have an increased risk of atherosclerotic disease, including coronary artery disease, special attention to eliminating conventional cardiovascular risk factors such as smoking, controlling hypertension and diabetes, statin use, and reducing weight in overweight patients is important. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV"
         </a>
         .)
        </p>
        <p>
         In light of the overall improved prognosis with the advent of potent ART, procedures such as coronary bypass or valve replacement should be done for the same indications as in uninfected subjects, unless the patient has advanced immunosuppression and high risk of mortality from AIDS-related complications [
         <a href="#rid79">
          79
         </a>
         ]. Circulatory assist devices and cardiac transplantation have been increasingly and successfully used in patients with HIV infection [
         <a href="#rid43">
          43,44,80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">
          "Heart transplantation in adults: Indications and contraindications", section on 'Chronic viral infection'
         </a>
         .)
        </p>
        <p>
         There is no definite direct evidence that ART leads to an improvement in cardiomyopathy, although the decline in the prevalence of HIV-associated cardiomyopathy following the introduction of potent ART suggest a benefit. Additionally, a study of five children with HIV and dilated cardiomyopathy reported reversal of left ventricular dilatation and decreased contractility after the initiation of combination ART [
         <a href="#rid81">
          81
         </a>
         ]. In another study of perinatally infected children, ART appeared cardioprotective, with better measures of left ventricular contractility among treated compared with untreated children [
         <a href="#rid82">
          82
         </a>
         ]. Initiation of ART is associated with a reduction in overall morbidity and mortality as well as public health benefits and is recommended for all patients with HIV. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H519454363">
         <span class="h1">
          PERICARDIAL DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H519454386">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to the introduction of potent antiretroviral therapy (ART), pericarditis was the most frequent clinical manifestation of cardiac disease in patients with HIV infection and, specifically, AIDS. However, in countries with widespread access to ART, the incidence of symptomatic pericardial disease in patients with HIV has decreased dramatically.
        </p>
        <p>
         In a study of 802 outpatients with HIV in Germany recruited between 2004 and 2006, 85 percent were receiving ART, 12 percent had a CD4 cell count &lt;200 cells/microL, and only two patients were found to have a pericardial effusion on transthoracic echocardiography [
         <a href="#rid83">
          83
         </a>
         ]. This is in contrast to pre-ART studies, in which the prevalence of pericardial effusions ranged from 10 to 40 percent; effusions were mainly observed in patients with AIDS [
         <a href="#rid84">
          84-88
         </a>
         ].
        </p>
        <p>
         In resource-limited settings, the prevalence of pericardial disease in patients with HIV is similar to that reported from pre-ART studies [
         <a href="#rid50">
          50,89
         </a>
         ]. In sub-Saharan Africa, it is the most common manifestation of cardiovascular disease in HIV infection [
         <a href="#rid90">
          90
         </a>
         ]. In a study of 518 patients with HIV who presented to a cardiology center in South Africa between 2006 and 2008 with a first manifestation of heart disease, pericardial disease was diagnosed in 128 patients (25 percent) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H519454404">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV-associated pericardial disease generally manifests as a pericardial effusion. Most patients are asymptomatic, identified incidentally through an increase in the cardiac silhouette on chest radiograph. Among those with symptomatic pericardial effusion, however, approximately one-third present with or develop cardiac tamponade [
         <a href="#rid91">
          91,92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p>
         Otherwise, clinical features of symptomatic HIV-associated pericardial disease are similar to those caused by other etiologies and include dyspnea, fever, pleuritic chest pain, and, in some cases, a pericardial friction rub. With cardiac tamponade, tachycardia, decrease in blood pressure, and elevated jugular venous pressure occur. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p>
         In cases of tuberculous pericarditis, myocarditis is also commonly present. In a study of 81 patients, 58 of whom had HIV, myocarditis (defined by echocardiographic left ventricular dysfunction immediately after pericardiocentesis, troponin T level &gt;0.03 ng/mL, or elevated creatine kinase-MB) was found in 53 percent [
         <a href="#rid93">
          93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">
          "Tuberculous pericarditis", section on 'Myopericarditis'
         </a>
         .)
        </p>
        <p>
         Constrictive pericarditis can also uncommonly occur with HIV-associated pericardial disease. Among 121 patients requiring pericardiectomy in a South Africa study, 14 (11.6 percent) of cases were HIV associated [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H568655049">
         <span class="h2">
          Etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the majority of asymptomatic patients, the etiology of pericardial effusion is not known or identified [
         <a href="#rid88">
          88
         </a>
         ]. Among symptomatic patients, approximately two-thirds are caused by infection or neoplasm.
        </p>
        <p>
         The differential of infectious and neoplastic etiologies of pericardial effusions in patients with HIV is broad [
         <a href="#rid11">
          11,21,91,92,95,96
         </a>
         ]. Mycobacteria are often the most common infectious pathogens involved [
         <a href="#rid42">
          42,92,97-99
         </a>
         ]. As an example, in a review of 185 cases of HIV-associated pericardial tamponade, mycobacterial infection including
         <em>
          Mycobacterium tuberculosis
         </em>
         ,
         <em>
          M. avium
         </em>
         -intracellulare, and
         <em>
          M. kansasii
         </em>
         accounted for 42 percent [
         <a href="#rid99">
          99
         </a>
         ]. Other etiologies included
         <em>
          Staphylococcus aureus
         </em>
         (11 percent), neoplasms such as lymphoma and Kaposi sarcoma (15 percent), and isolated cases of
         <em>
          Cryptococcus
         </em>
         ,
         <em>
          Nocardia
         </em>
         , and
         <em>
          Aspergillus
         </em>
         species. In 26 percent, no etiology was identified.
        </p>
        <p>
         Geography impacts the likelihood of specific mycobacterial infection. In sub-Saharan Africa, tuberculosis is the major cause of pericarditis among patients with HIV infection [
         <a href="#rid100">
          100
         </a>
         ], accounting for 70 to 90 percent of pericardial effusions in patients with HIV in some studies [
         <a href="#rid90">
          90,101
         </a>
         ]. By contrast, in resource-rich settings, only approximately 5 percent of patients with HIV and pericarditis have tuberculosis [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         Other infectious etiologies that have been associated with pericardial effusions in patients with HIV include
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Listeria monocytogenes
         </em>
         ,
         <em>
          Rhodococcus equi
         </em>
         , and
         <em>
          Chlamydia trachomatis
         </em>
         .
        </p>
        <p>
         Primary effusion lymphoma is a rare high-grade B-cell non-Hodgkin lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpes virus 8 infection, mostly seen with patients with HIV with low CD4 cell counts, and can be associated with pericardial effusion [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H568654938">
         <span class="h2">
          Diagnosis and evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis and evaluation of a pericardial effusion in an individual with HIV are the same as those in the general population. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p>
         Although most patients with HIV and pericardial effusions are incidentally identified, there is no indication to screen asymptomatic patients for an effusion with chest radiograph or echocardiography.
        </p>
        <p>
         For symptomatic patients, an attempt at establishing the etiology should be made. This generally includes pericardiocentesis or biopsy to obtain fluid and/or tissue for microbiological and cytological or pathological analysis. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p>
         Tuberculous pericarditis remains an important disease in areas where tuberculosis is endemic, although it may be difficult to diagnose in patients with HIV [
         <a href="#rid90">
          90
         </a>
         ]. Cutaneous anergy to the
         <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">
          tuberculin skin test
         </a>
         is common in the setting of AIDS (61 percent in one series) [
         <a href="#rid104">
          104
         </a>
         ]; as a result, a negative tuberculin skin test does not exclude the diagnosis. Pericardial biopsy is more sensitive than smears and culture of pericardial fluid but may not be positive for caseating granulomata. The diagnosis of tuberculous pericarditis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">
          "Tuberculous pericarditis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H519454410">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of pericardial effusion in patients with HIV varies by the severity and etiology of the disease. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p>
         The majority of patients with a pericardial effusion have small effusions causing no symptoms. An asymptomatic, small pericardial effusion without tamponade often requires no further testing except for follow-up [
         <a href="#rid86">
          86,105
         </a>
         ].
        </p>
        <p>
         By contrast, for patients who are symptomatic with a large effusion, even without tamponade, pericardiocentesis is indicated to evaluate for the etiology, as above. If tamponade occurs, immediate drainage is indicated. Management of cardiac tamponade is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p>
         Additional management is warranted depending on the identified or suspected etiology.
        </p>
        <p>
         As an example, antituberculous therapy is indicated in patients with pericardial disease due to
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid106">
          106-108
         </a>
         ]. Additionally, it is generally recommended that patients with a large pericardial effusion in whom no etiology is established be treated empirically for tuberculosis. Details on the management of suspected or confirmed tuberculous pericarditis, including the role of corticosteroids for constrictive tuberculous pericarditis, are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">
          "Tuberculous pericarditis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Other causes of pericarditis in patients with HIV should also be treated when identified. Bacterial or fungal infection should be treated with appropriate antimicrobial agents. Management of primary effusion lymphoma, which can cause pericardial effusion in patients with HIV, is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4752.html" rel="external">
          "Primary effusion lymphoma", section on 'Management'
         </a>
         .)
        </p>
        <p>
         If the patient is not already taking ART, this therapy should be started. Initiation of ART is associated with a reduction in overall morbidity and mortality as well as public health benefits and is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H519454416">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of pericardial effusion in a patient with HIV is a poor prognostic sign, even if asymptomatic [
         <a href="#rid87">
          87,99,105
         </a>
         ]. In a series of 195 patients with HIV from the pre-ART era, mortality in the patients with pericardial effusion was significantly higher than in the patients with AIDS who did not have an effusion (64 versus 7 percent at six months) [
         <a href="#rid87">
          87
         </a>
         ]. The shortened survival remained significant (relative risk [RR] 2.2) after adjustment for lead time bias and risk factors. The pericardial effusions rarely directly contribute to mortality but rather serve as a marker of advanced HIV infection. Nevertheless, certain etiologies of pericardial disease carry especially poor prognoses. As an example, the median survival of patients with effusion related to primary effusion lymphoma is less than six months [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          PULMONARY HYPERTENSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevation of pulmonary artery pressures has been reported in a large minority of patients with HIV [
         <a href="#rid109">
          109
         </a>
         ], but clinically significant pulmonary arterial hypertension is a relatively uncommon complication of HIV infection. It can occur at all stages of infection, does not seem to be related to the degree of immunodeficiency, and carries a poor prognosis [
         <a href="#rid110">
          110
         </a>
         ]. In a prospective French study done in the antiretroviral therapy (ART) era that involved over 7000 patients with HIV, the estimated prevalence of pulmonary hypertension was very low (0.46 percent), approximately the same as it was in the 1990s [
         <a href="#rid111">
          111,112
         </a>
         ]. The histopathologic picture is similar to that seen in idiopathic pulmonary hypertension, with obstruction of the pulmonary vasculature by endothelial proliferation, medial hypertrophy, and plexiform lesions [
         <a href="#rid113">
          113
         </a>
         ]. This condition is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8246.html" rel="external">
          "Pulmonary arterial hypertension associated with human immunodeficiency virus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H568653260">
         <span class="h1">
          OTHER CARDIAC AND VASCULAR DISEASES
         </span>
        </p>
        <p class="headingAnchor" id="H568653330">
         <span class="h2">
          Venous thromboembolic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV appear to have an increased risk of venous thromboembolic disease [
         <a href="#rid114">
          114-118
         </a>
         ]. Some studies have estimated that the risk is 2 to 10-fold higher than that in the general population, although the majority of thromboembolic events associated with patients with HIV were noted among those with CD4 cell counts &lt;200 cells/microL or an AIDS-defining illness [
         <a href="#rid119">
          119-121
         </a>
         ].
        </p>
        <p>
         As an example, in a retrospective assessment of data from the National Hospital Discharge Survey from 1996 to 2004, the odds ratio of developing a pulmonary embolism was 43 percent greater among patients with HIV compared with age-matched controls [
         <a href="#rid122">
          122
         </a>
         ]. Patients with HIV also had a 10 percent greater risk of developing deep vein thrombosis.
        </p>
        <p>
         Factors that have been implicated in the development of thrombotic complications in patients with HIV, in addition to opportunistic infections, malignancy, and an indwelling central venous catheter, include [
         <a href="#rid121">
          121,123-127
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower CD4 counts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated HIV RNA levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated levels of factor VIII and homocysteine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated lipid levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated D-dimer and other markers of dysregulated coagulation and fibrinolysis [
         <a href="#rid128">
          128-131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of antiphospholipid antibodies (anticardiolipin antibodies [aCL] or lupus anticoagulants [LA]) or autoimmune hemolytic anemia. (See
         <a class="medical medical_review" href="/z/d/html/4676.html" rel="external">
          "Pathogenesis of antiphospholipid syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevated levels of aCL are often encountered in patients with chronic infections and have been described in as many as 64 percent of patients with HIV [
         <a href="#rid132">
          132,133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired deficiencies of proteins S and C and antithrombin [
         <a href="#rid124">
          124,134-136
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of venous thromboembolic disease in patients with HIV are the same as for the general population and are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H568653551">
         <span class="h2">
          Peripheral artery disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the general population, peripheral artery disease (PAD) is associated with traditional cardiovascular risk factors, such as smoking, diabetes, hypertension, and hypercholesterolemia. Many of these risk factors are more prevalent among individuals with HIV compared with the general population, and HIV infection itself appears to be an independent risk factor for PAD [
         <a href="#rid137">
          137,138
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         .)
        </p>
        <p>
         Most [
         <a href="#rid139">
          139-142
         </a>
         ], but not all [
         <a href="#rid143">
          143
         </a>
         ], suggest a relatively high burden of PAD among this population. In a study of over 90,000 participants in the Veterans Aging Cohort Study, the rate of PAD was higher among those with HIV than without (11.9 versus 9.9 events per 1000 person-years), although the excess risk was confined to individuals with CD4 cell counts &lt;200 cells/microL and HIV viral levels &gt;500 copies/mL [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
         In one study of 92 adults with HIV (mean age 50 years), the prevalence of PAD was evaluated through a claudication questionnaire and measurement of the systolic ankle-brachial index (ABI) at rest and after exercise [
         <a href="#rid140">
          140
         </a>
         ]. Patients with PAD by ABI were further evaluated with duplex scanning of the lower-limb arteries (see
         <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">
          "Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Ankle-brachial index'
         </a>
         ). The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Claudication was reported by 15 percent of patients through the questionnaire.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Twenty-one percent of patients with HIV had peripheral vascular disease compared with the expected prevalence in the general population of 3 percent at age 60.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among the 16 patients who had an abnormal ABI, all had evidence of atherosclerotic occlusions/stenoses of the iliac or femoral arteries on duplex scanning. Age, diabetes, smoking, and low CD4 cell counts were identified as independent predictors of disease.
        </p>
        <p>
        </p>
        <p>
         Potential mechanisms that predispose to the development of vascular disease include the recognized vascular risk factors, the negative impact of certain antiretroviral therapy (ART) medications on lipid metabolism, and the direct effect of HIV on the arterial wall. In a study of 54 patients with HIV and without a history of cardiovascular disease and 54 controls closely matched for age, gender, body mass index (BMI), and vascular risk factors, HIV infection was associated with decreased arterial compliance, while all other arterial stiffness parameters were similar in both groups and correlated with age [
         <a href="#rid144">
          144
         </a>
         ]. Decreased arterial compliance may contribute to the development of atherosclerosis and PAD. (See
         <a class="medical medical_review" href="/z/d/html/83686.html" rel="external">
          "Pathogenesis and biomarkers of cardiovascular disease in patients with HIV"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of PAD in patients with HIV are the same as for the general population and are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">
          "Clinical features and diagnosis of lower extremity peripheral artery disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">
          "Management of claudication due to peripheral artery disease"
         </a>
         .)
        </p>
        <p>
         Additionally, the incidence of ischemic stroke among patients with HIV has been increasing, likely reflecting the prevalence of disease of the carotid arteries [
         <a href="#rid145">
          145,146
         </a>
         ]. In one study of 209 patients with HIV infection but without known vascular disease, the rate of carotid plaques and noncalcified high-risk plaques identified by computed tomography was higher than in uninfected controls; at three years, any plaques were associated with a fourfold increase in the risk of strokes [
         <a href="#rid147">
          147
         </a>
         ]. In a meta-analysis of five studies including nearly 90,000 adults with HIV (approximately 46 to 50 years old) on ART, 1.8 percent had ischemic strokes after a median follow-up of four years [
         <a href="#rid148">
          148
         </a>
         ]. Traditional risk factors such as age, smoking, hypertension, hyperlipidemia, atrial fibrillation, and diabetes were independent predictors of stroke. In one of the included studies, high HIV viral load and CD4 cell count &lt;200 cells/microL were associated with stroke; ART had a neutral effects [
         <a href="#rid148">
          148
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Valvular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, valvular diseases among patients with HIV are similar to those among the general population. In a prospective multicenter study of 803 adults with HIV, 77.2 percent had mild valvular regurgitation on transthoracic echocardiography, but only 4.7 percent had clinically relevant regurgitation and 0.4 percent had clinically significant stenosis [
         <a href="#rid149">
          149
         </a>
         ]. There was no association between CD4 cell count or viral load and the presence of valvular disease.
        </p>
        <p>
         Overall, the risk and incidence of infective endocarditis among patients with HIV is similar to HIV-uninfected populations who share similar risk behaviors, particularly injection drug use [
         <a href="#rid85">
          85,150-153
         </a>
         ]. In a study of 105 patients with HIV and infective endocarditis, the mean age was 30.1 years and 94 percent had a history of injection drug use [
         <a href="#rid150">
          150
         </a>
         ]. A very low CD4 cell count (&lt;50 cells/microL) and high HIV RNA levels (&gt;100,000 copies/mL) have been associated with an increased risk of infective endocarditis, and the incidence has appeared to decline since the introduction of ART in resource-rich settings [
         <a href="#rid151">
          151
         </a>
         ]. As with infective endocarditis in injection drug users without HIV, the most common valve involved is the tricuspid valve and the most common organism
         <em>
          S. aureus
         </em>
         [
         <a href="#rid150">
          150,151
         </a>
         ]. Clinicians should consider the possibility of methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) in patients with HIV and endocarditis, as the pathogen is relatively common among this population [
         <a href="#rid151">
          151,154
         </a>
         ].
        </p>
        <p>
         The treatment approach to infective endocarditis, including the indications for valve surgery, is the same for patients with and without HIV. Overall, response to antibiotic therapy is similar among injection drug users with and without HIV [
         <a href="#rid153">
          153,155
         </a>
         ]. One study reported a higher mortality rate in the setting of endocarditis among injection drug users with HIV compared with those without HIV, but all deaths were among patients with a CD4 cell count &lt;200 cells/microL [
         <a href="#rid156">
          156
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2149.html" rel="external">
          "Right-sided native valve infective endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         In the United States, between 2000 and 2010, the proportion of patients with HIV undergoing surgery for endocarditis decreased from 32 to 8 percent and operative mortality among patients with HIV decreased from 5.6 to 0.9 percent [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p>
         Nonbacterial thrombotic (marantic) endocarditis, which consists of sterile vegetations and can occur on any of the valves, was found on autopsy in up to 10 percent of AIDS patients at the outset of the HIV epidemic in the United States. There have been no cases reported in patients with HIV since 1989 [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H568653151">
         <span class="h2">
          Cardiac rhythm disturbances
         </span>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Long QT syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         QT prolongation and torsade de pointes (TdP) have been described in patients with HIV, even in the absence of therapy with agents associated with these features. In a study of 135 consecutive patients with HIV seen at an outpatient clinic, 17 to 29 percent had a prolonged QT interval [
         <a href="#rid158">
          158
         </a>
         ]. In a study of 351 patients with HIV, 26 (7.4 percent) had a prolonged corrected QT interval [
         <a href="#rid159">
          159
         </a>
         ]. Similarly, in a study of hospitalized patients with HIV, 29 percent had QT prolongation [
         <a href="#rid160">
          160
         </a>
         ]. Postulated mechanisms include myocarditis, a subclinical cardiomyopathy, and autonomic neuropathy [
         <a href="#rid161">
          161
         </a>
         ]. There is evidence an HIV protein (tat) inhibits KCNH2 (formerly hERG) protein expression and thus inhibits KCNH2 potassium currents, which could be a potential mechanism for HIV-associated long QT findings [
         <a href="#rid162">
          162
         </a>
         ]. A low CD4 cell count and high viral load have been associated with prolonged QT interval [
         <a href="#rid94">
          94,159
         </a>
         ]. Among ART-treated patients with viral suppression, prolonged QT interval has been associated with hyperlipidemia and diastolic dysfunction, whereas
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         use was associated with a lower rate of QT prolongation [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
         In addition, certain therapeutic agents used in HIV infection may contribute to the development of QT prolongation.
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         may promote TdP both directly and by causing hypomagnesemia [
         <a href="#rid164">
          164,165
         </a>
         ], and certain HIV protease inhibitors, such as
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         with
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         , and lopinavir with ritonavir, block the KCNH2 channel and could thus directly cause the long QT syndrome [
         <a href="#rid165">
          165,166
         </a>
         ]. However, in a large study that randomly assigned HIV-infected patients to receive either intermittent ART or continuous ART, different protease inhibitor-based regimens were not independently associated with prolongation in the QT interval compared with regimens that did not contain a protease inhibitor [
         <a href="#rid167">
          167,168
         </a>
         ]. However, all protease inhibitor-based regimens were associated with prolongation of the PR interval. Nevertheless, protease inhibitors may also inhibit the CYP p450 metabolism of drugs known to prolong the QTc interval (eg,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ), thereby increasing the risk of QTc prolongation. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Protease inhibitors (PIs)'
         </a>
         .)
        </p>
        <p>
         Precautions for patients using drugs associated with QT prolongation and management of patients with QT syndrome are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
         The main concern with prolonged QT is the development of life-threatening arrhythmias and sudden cardiac death. In a study of almost 3000 patients with HIV, there were 2.6 sudden cardiac deaths per 1000 person-years, 4.5 times the rate in the general population [
         <a href="#rid169">
          169
         </a>
         ]. Compared with death from AIDS and natural causes, sudden cardiac death was associated with a history of prior myocardial infarction, cardiomyopathy, heart failure, and arrhythmias. Postulated mechanisms included inflammation, ART interruption, and concomitant medications.
        </p>
        <p class="headingAnchor" id="H282128138">
         <span class="h3">
          Atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall incidence of atrial fibrillation among individuals with HIV is low. In a study of 30,533 United States veterans with HIV, 2.6 percent developed atrial fibrillation over a median follow-up of 6.8 years [
         <a href="#rid170">
          170
         </a>
         ]. CD4 cell count &lt;200 cells/microL and viral load &gt;100,000 copies/mL were associated with atrial fibrillation.
        </p>
        <p>
         In the general population, the CHA2S2-VASc score is often used to determine the risk of embolic stroke with atrial fibrillation and thus to guide decisions on anticoagulation. Given that HIV infection is associated with a baseline risk of stroke that is not accounted for in traditional risk score calculators, anticoagulation may thus be warranted for patients with HIV despite a low CHA2S2-VASc score [
         <a href="#rid171">
          171
         </a>
         ]. In a study of 914 veterans with HIV and atrial fibrillation, the CHA2DS2-VASc scores were only weakly associated with thromboembolic risk [
         <a href="#rid172">
          172
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">
          "Atrial fibrillation in adults: Selection of candidates for anticoagulation"
         </a>
         .)
        </p>
        <p>
         When selecting anticoagulation for patients with HIV, consideration of drug interactions with antiretroviral agents is essential. For specific drug interactions, refer to the
         <a class="external" href="/drug-interactions">
          Lexicomp drug interactions
         </a>
         program included with UpToDate.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Autonomic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autonomic nervous system dysfunction appears relatively common among patients with HIV [
         <a href="#rid173">
          173
         </a>
         ]. A meta-analysis of studies on heart rate variation in patients with HIV found a general reduction in autonomic function with a shift toward sympathetic dominance that may predispose patients with HIV to the risk of arrhythmias, cardiac events, and accelerated HIV disease progression [
         <a href="#rid174">
          174
         </a>
         ].
        </p>
        <p>
         Some evidence suggests that the lower heart rate variability with HIV is indicative of autonomic nervous system inflammatory-immune dysfunction [
         <a href="#rid175">
          175
         </a>
         ]. Another study suggested that the decreased parasympathetic function compared with HIV-uninfected patients was evident among both viremic and aviremic patients with HIV [
         <a href="#rid176">
          176
         </a>
         ]. ART did not appear to affect autonomic function [
         <a href="#rid177">
          177
         </a>
         ]. The proposed mechanism for the autonomic dysfunction is unknown but may be related to the HIV-induced changes in the brain responsible for autonomic nervous system function. It has also been associated with distal symmetric polyneuropathy [
         <a href="#rid173">
          173
         </a>
         ].
        </p>
        <p>
         Despite the prevalence of autonomic dysfunction among patients with HIV, it is rarely recognized by clinicians, and symptoms often remain unexplained or attributed to medication side effects [
         <a href="#rid178">
          178
         </a>
         ]. Nevertheless, it carries significant morbidity and can lead to QTc prolongation and malignant ventricular arrhythmias.
        </p>
        <p class="headingAnchor" id="H2023664971">
         <span class="h2">
          Sudden cardiac death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sudden death is an important cardiovascular complication among patients with HIV, who appear to be at higher risk compared with the general population [
         <a href="#rid179">
          179,180
         </a>
         ]. In the Veterans Aging Cohort Study, which followed over 144,000 veterans for a median of nine years, HIV was associated with an increased risk of sudden cardiac death (hazard ratio 1.14, 95% CI 1.04-1.25) [
         <a href="#rid180">
          180
         </a>
         ]. The increased risk was predominantly seen in veterans with HIV and with CD4 counts &lt;200 cells/microL and viral load &gt;500 copies/mL. Risk of sudden cardiac death in veterans with HIV and with CD4 counts &gt;500 cells/microL or viral load &lt;500 copies/mL were comparable to veterans who did not have HIV [
         <a href="#rid180">
          180
         </a>
         ]. In a postmortem study of individuals with HIV who had out-of-hospital cardiac arrest, the rate of sudden cardiac death was estimated at 53.3 per 100,000 person-years compared with 23.7 per 100,000 person-years among individuals without known HIV [
         <a href="#rid179">
          179
         </a>
         ]. Among the 47 individuals with HIV and sudden cardiac death who underwent autopsy, the cause was arrhythmia for 47 percent and noncardiac for 51 percent. The most common underlying case was occult drug overdose (in one-third of cases).
        </p>
        <p>
         Sudden cardiac deaths appear to account for a majority of cardiac deaths in patients with HIV. In a study of 230 deaths over a median of 3.7 years among patients with HIV infection, 30 of the 35 cardiac deaths (86 percent) were sudden deaths [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H568653794">
         <span class="h2">
          Cardiac tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain malignancies associated with HIV infection, namely Kaposi sarcoma and non-Hodgkin lymphoma, may present with cardiac involvement. However, following the introduction of combination ART, the incidence of cardiac tumor involvement in patients with HIV in resource-rich countries has dropped substantially, possibly as a result of less immunologic depression and a marked decrease in opportunistic infections such as Epstein-Barr virus and human herpes virus 8 that are known to be etiologically related to these neoplasms [
         <a href="#rid181">
          181
         </a>
         ].
        </p>
        <p>
         Prior to the widespread use of ART in resource-rich settings, Kaposi sarcoma was observed to involve the myocardium or the pericardium and cause pericardial effusion and, in some cases, tamponade among patients with AIDS [
         <a href="#rid92">
          92,182
         </a>
         ]. In autopsy reports from that era, the prevalence of Kaposi sarcoma in patients with AIDS was 12 to 28 percent [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Similarly, there are reports of primary cardiac lymphoma among patients with AIDS [
         <a href="#rid183">
          183-186
         </a>
         ]. Lymphomas are the second most common cardiac tumors in AIDS, and despite effective ART, the incidence of non-Hodgkin lymphoma among individuals with HIV remains higher than among the noninfected population. When lymphoma involves the heart, it is usually diffusely infiltrative but can form nodules and even intracavitary masses [
         <a href="#rid21">
          21,187,188
         </a>
         ]. Cardiac lymphoma can cause heart failure, superior vena caval syndrome, atrial and ventricular arrhythmias, and heart block. With intracavitary growth, the masses can cause mechanical obstruction to the blood flow across the valves. In such cases, surgical resection may be indicated. Since the introduction of ART and more advanced chemotherapy, the prognosis in patients with non-Hodgkin lymphoma has improved [
         <a href="#rid189">
          189,190
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4750.html" rel="external">
          "HIV-related lymphomas: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4753.html" rel="external">
          "HIV-related lymphomas: Treatment of systemic lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2087337046">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111628.html" rel="external">
          "Society guideline links: Primary care of adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15331.html" rel="external">
          "Patient education: Coronary artery disease (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86003.html" rel="external">
          "Patient education: Heart failure with preserved ejection fraction (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3427.html" rel="external">
          "Patient education: Pericarditis (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/3446.html" rel="external">
          "Patient education: Heart failure (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25350235">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In resource-rich countries, coronary artery disease has emerged as the major cause of cardiac-related morbidity and mortality in HIV-infected patients. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericardial and myocardial disease had historically been the most frequent clinical manifestations of heart disease in patients with HIV, but their prevalence has decreased dramatically with the widespread use of antiretroviral therapy (ART). Nevertheless, they remain common in settings where access to diagnosis and treatment of HIV infection is limited. (See
         <a class="local">
          'Types of cardiac disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although the prevalence of HIV-associated myocardial disease has dropped significantly since the widespread use of ART, subtle abnormalities in myocardial structure and function on echocardiography and imaging are still observed among treated individuals with HIV. Nevertheless, routine echocardiography in asymptomatic patients with HIV is not indicated, as there appears to be no advantage to finding subclinical disease. (See
         <a class="local">
          'Myocardial disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac ischemia may emerge as an important cause of clinical cardiomyopathy in treated patients with HIV. The clinical presentation, diagnosis and evaluation, and management of heart failure in patients with HIV are generally the same as in the general population. However, the potential involvement of opportunistic infections should be considered among patients with HIV and CD4 cell counts &lt;200 cells/microL. (See
         <a class="local">
          'Myocardial disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericardial disease among patients with HIV generally manifests as a pericardial effusion in patients with significant immunosuppression, often found incidentally. The majority of symptomatic pericardial effusions are due to infection (particularly tuberculosis) or malignancy. The diagnosis and evaluation of a pericardial effusion in an individual with HIV are the same as those in the general population. The management of pericardial effusion in patients with HIV varies by the severity and etiology of the disease. (See
         <a class="local">
          'Pericardial disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">
          "Tuberculous pericarditis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary arterial hypertension is a relatively uncommon complication of HIV infection that can occur at all stages of infection, does not seem to be related to the degree of immunodeficiency, and carries a poor prognosis. (See
         <a class="medical medical_review" href="/z/d/html/8246.html" rel="external">
          "Pulmonary arterial hypertension associated with human immunodeficiency virus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other cardiac and vascular processes that have been associated with HIV infection include venous thromboembolic disease, peripheral artery disease (PAD), infective endocarditis (almost exclusively in injection drug users), cardiac rhythm disturbances, and, very rarely, cardiac tumors. (See
         <a class="local">
          'Other cardiac and vascular diseases'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000; 43:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manga P, McCutcheon K, Tsabedze N, et al. HIV and Nonischemic Heart Disease. J Am Coll Cardiol 2017; 69:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield GS, Alenezi F, Barasa FA, et al. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. JACC Heart Fail 2015; 3:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 Suppl 3:S375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson MD, Szczepaniak LS, LaBounty TM, et al. Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. JACC Cardiovasc Imaging 2014; 7:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal M, Bhaskaran A, Khalife WI, Barbagelata A. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev 2009; 5:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med 2011; 19:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstein MJ, Bogorodskaya M, Bloomfield GS, et al. Cardiovascular Complications of HIV in Endemic Countries. Curr Cardiol Rep 2016; 18:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann N Y Acad Sci 2001; 946:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lekakis J, Ikonomidis I. Cardiovascular complications of AIDS. Curr Opin Crit Care 2010; 16:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worm SW, Lundgren JD. The metabolic syndrome in HIV. Best Pract Res Clin Endocrinol Metab 2011; 25:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adih WK, Selik RM, Hu X. Trends in Diseases Reported on US Death Certificates That Mentioned HIV Infection, 1996-2006. J Int Assoc Physicians AIDS Care (Chic) 2011; 10:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escárcega RO, Franco JJ, Mani BC, et al. Cardiovascular disease in patients with chronic human immunodeficiency virus infection. Int J Cardiol 2014; 175:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freiberg MS, Chang CH, Skanderson M, et al. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiol 2017; 2:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler J, Kalogeropoulos AP, Anstrom KJ, et al. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. J Card Fail 2018; 24:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guha S, Pande A, Mookerjee S, et al. Echocardiographic profile of ART naïve human immunodeficiency virus (HIV) infected patients in a tertiary care hospital in Kolkata. Indian Heart J 2010; 62:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sliwa K, Carrington MJ, Becker A, et al. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012; 33:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis W. AIDS: cardiac findings from 115 autopsies. Prog Cardiovasc Dis 1989; 32:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson DW, Virmani R, Reilly JM, et al. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol 1988; 11:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998; 14:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanjewar DN, Katdare GA, Jain PP, Hira SK. Pathology of the heart in acquired immunodeficiency syndrome. Indian Heart J 1998; 50:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holloway CJ, Ntusi N, Suttie J, et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation 2013; 128:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaboodien G, Maske C, Wainwright H, et al. Prevalence of myocarditis and cardiotropic virus infection in Africans with HIV-associated cardiomyopathy, idiopathic dilated cardiomyopathy and heart transplant recipients: a pilot study: cardiovascular topic. Cardiovasc J Afr 2013; 24:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lumsden RH, Bloomfield GS. The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds. Biomed Res Int 2016; 2016:8196560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mondy KE, Gottdiener J, Overton ET, et al. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis 2011; 52:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuster I, Thöni GJ, Edérhy S, et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008; 101:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinsch N, Neuhaus K, Esser S, et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials 2010; 11:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo L, Zeng Y, Li T, et al. Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV. Clin Infect Dis 2014; 58:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerrato E, D'Ascenzo F, Biondi-Zoccai G, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twagirumukiza M, Nkeramihigo E, Seminega B, et al. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007; 5:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal P, Sharma A, Bhardwaj R, Raina R. Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study. J Assoc Physicians India 2009; 57:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luetkens JA, Doerner J, Schwarze-Zander C, et al. Cardiac Magnetic Resonance Reveals Signs of Subclinical Myocardial Inflammation in Asymptomatic HIV-Infected Patients. Circ Cardiovasc Imaging 2016; 9:e004091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntusi N, O'Dwyer E, Dorrell L, et al. HIV-1-Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial Edema. Circ Cardiovasc Imaging 2016; 9:e004430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Currie PF, Jacob AJ, Foreman AR, et al. Heart muscle disease related to HIV infection: prognostic implications. BMJ 1994; 309:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardoso JS, Moura B, Martins L, et al. Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. Int J Cardiol 1998; 63:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herskowitz A, Vlahov D, Willoughby S, et al. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 1993; 71:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 1998; 339:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J 2006; 151:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remick J, Georgiopoulou V, Marti C, et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. Circulation 2014; 129:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vachiat A, McCutcheon K, Tsabedze N, et al. HIV and Ischemic Heart Disease. J Am Coll Cardiol 2017; 69:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah MR. The Broad Spectrum of HIV-Related Cardiovascular Disease. JACC Heart Fail 2015; 3:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorgis L, Cottenet J, Molins G, et al. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation 2013; 127:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese LH, Proffitt MR, Yen-Lieberman B, et al. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med 1987; 107:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dittrich H, Chow L, Denaro F, Spector S. Human immunodeficiency virus, coxsackievirus, and cardiomyopathy. Ann Intern Med 1988; 108:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 1985; 109:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009; 6:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofman P, Drici MD, Gibelin P, et al. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J 1993; 70:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore) 1994; 73:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldblum N, Daefler S, Llana T, et al. Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus. Dev Biol Stand 1990; 72:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cenacchi G, Re MC, Furlini G, et al. Human immunodeficiency virus type 1 antigen detection in endomyocardial biopsy: an immunomorphological study. Microbiologica 1990; 13:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AY, Forouhar F, Cartun RW, et al. Identification of human immunodeficiency virus in the heart of a patient with acquired immunodeficiency syndrome. Mod Pathol 1990; 3:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiala M, Popik W, Qiao JH, et al. HIV-1 induces cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovasc Toxicol 2004; 4:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990; 66:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez ER, Nasim S, Hsia J, et al. Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. Am J Cardiol 1991; 68:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon RP, Mathier MA, Manleod S, et al. Macrophages not cardiomyocytes are the reservoir for lentivirus in SIV cardiomyopathy. Circulation 1999; 100:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lähdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monsuez JJ, Escaut L, Teicher E, et al. Cytokines in HIV-associated cardiomyopathy. Int J Cardiol 2007; 120:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaro G, Di Lorenzo G, Soldini M, et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation 1999; 100:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twu C, Liu NQ, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci U S A 2002; 99:14386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olinski R, Gackowski D, Foksinski M, et al. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome. Free Radic Biol Med 2002; 33:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozzan G, Pagliari C, Tuon FF, et al. Diffuse-regressive alterations and apoptosis of myocytes: possible causes of myocardial dysfunction in HIV-related cardiomyopathy. Int J Cardiol 2009; 132:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers JS, Zakaria S, Thom KA, et al. Immune reconstitution inflammatory syndrome and human immunodeficiency virus-associated myocarditis. Mayo Clin Proc 2008; 83:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herskowitz A, Willoughby S, Wu TC, et al. Immunopathogenesis of HIV-1-associated cardiomyopathy. Clin Immunol Immunopathol 1993; 68:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci 2003; 73:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008; 172:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987; 83:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herskowitz A, Willoughby SB, Baughman KL, et al. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992; 116:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000; 80:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domanski MJ, Sloas MM, Follmann DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995; 127:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanaugh-McHugh AL, Ruff A, Perlman E, et al. Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 1991; 15:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chariot P, Perchet H, Monnet I. Dilated cardiomyopathy in HIV-infected patients. N Engl J Med 1999; 340:732; author reply 733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Secemsky EA, Scherzer R, Nitta E, et al. Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC Heart Fail 2015; 3:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filsoufi F, Salzberg SP, Harbou KT, et al. Excellent outcomes of cardiac surgery in patients infected with HIV in the current era. Clin Infect Dis 2006; 43:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agüero F, Castel MA, Cocchi S, et al. An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients. Am J Transplant 2016; 16:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plebani A, Esposito S, Pinzani R, et al. Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection. Pediatr Infect Dis J 2004; 23:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipshultz SE, Williams PL, Wilkinson JD, et al. Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study. JAMA Pediatr 2013; 167:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lind A, Reinsch N, Neuhaus K, et al. Pericardial effusion of HIV-infected patients ? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res 2011; 16:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Himelman RB, Chung WS, Chernoff DN, et al. Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study. J Am Coll Cardiol 1989; 13:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Castro S, Migliau G, Silvestri A, et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 1992; 13:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsia J, Ross AM. Pericardial effusion and pericardiocentesis in human immunodeficiency virus infection. Am J Cardiol 1994; 74:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995; 92:3229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estok L, Wallach F. Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection. Mt Sinai J Med 1998; 65:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J 2013; 34:3538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syed FF, Sani MU. Recent advances in HIV-associated cardiovascular diseases in Africa. Heart 2013; 99:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenberg MJ, Gordon AS, Schiller NB. HIV-associated pericardial effusions. Chest 1992; 102:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Brennessel D, Walters J, et al. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999; 137:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syed FF, Ntsekhe M, Gumedze F, et al. Myopericarditis in tuberculous pericardial effusion: prevalence, predictors and outcome. Heart 2014; 100:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutyaba AK, Balkaran S, Cloete R, et al. Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa: causes and perioperative outcomes in the HIV era (1990-2012). J Thorac Cardiovasc Surg 2014; 148:3058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flum DR, McGinn JT Jr, Tyras DH. The role of the 'pericardial window' in AIDS. Chest 1995; 107:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gouny P, Lancelin C, Girard PM, et al. Pericardial effusion and AIDS: benefits of surgical drainage. Eur J Cardiothorac Surg 1998; 13:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher D, Harries AD. Tuberculous pericardial effusion: a prospective clinical study in a low-resource setting--Blantyre, Malawi. Int J Tuberc Lung Dis 1997; 1:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sá I, Môço R, Cabral S, et al. Constrictive pericarditis of tuberculous etiology in the HIV-positive patient: case report and review of the literature. Rev Port Cardiol 2006; 25:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gowda RM, Khan IA, Mehta NJ, et al. Cardiac tamponade in patients with human immunodeficiency virus disease. Angiology 2003; 54:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev 2013; 18:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 2005; 133:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagristà-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Tuberculous pericarditis: ten year experience with a prospective protocol for diagnosis and treatment. J Am Coll Cardiol 1988; 11:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulanger E, Gérard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23:4372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cegielski JP, Lwakatare J, Dukes CS, et al. Tuberculous pericarditis in Tanzanian patients with and without HIV infection. Tuber Lung Dis 1994; 75:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard DG, Hagenhoff C, Chow LC, et al. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J Am Coll Cardiol 1991; 17:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Prog Cardiovasc Dis 2007; 50:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisch B, Seferović PM, Ristić AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008; 22:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect 2011; 17:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almodovar S, Cicalini S, Petrosillo N, Flores SC. Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective. Chest 2010; 137:6S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dillmon MS, Saag MS, Hamza SH, et al. Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature. AIDS Res Hum Retroviruses 2005; 21:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Micieli E, Dentali F, Giola M, et al. Venous and arterial thrombosis in patients with HIV infection. Blood Coagul Fibrinolysis 2007; 18:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bibas M, Biava G, Antinori A. HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis 2011; 3:e2011030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy 2010; 30:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvaro-Meca A, Ryan P, Martínez-Larrull E, et al. Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997-2013): A nationwide population-based study in Spain. Eur J Intern Med 2018; 48:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saber AA, Aboolian A, LaRaja RD, et al. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malek J, Rogers R, Kufera J, Hirshon JM. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2011; 29:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fultz SL, McGinnis KA, Skanderson M, et al. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004; 39:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein SK, Slim EJ, de Kruif MD, et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahonkhai AA, Gebo KA, Streiff MB, et al. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr 2008; 48:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008; 22:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker JV, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS 2010; 5:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res 2014; 133 Suppl 1:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker JV, Huppler Hullsiek K, Bradford RL, et al. Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr 2013; 63:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez V, Diemert MC, Braibant M, et al. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis 2009; 48:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdollahi A, Morteza A. Serum concentrations of antiphospholipid and anticardiolipin antibodies are higher in HIV-infected women. Rheumatol Int 2012; 32:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lijfering WM, Sprenger HG, Georg RR, et al. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 2008; 54:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ye Y, Zeng Y, Li X, et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr 2010; 53:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Bajaj S, Shah P, et al. The Prevalence of Peripheral Arterial Disease in HIV Patients. J Vasc Surg 2013; 1:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Periard D, Cavassini M, Taffé P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaqa AY, DeBari VA, Isbitan A, et al. The role of postexercise measurements in the diagnosis of peripheral arterial disease in HIV-infected patients. Angiology 2011; 62:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckman JA, Duncan MS, Alcorn CW, et al. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation 2018; 138:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernal E, Masiá M, Padilla S, et al. Low prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors. J Acquir Immune Defic Syndr 2008; 47:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferraioli G, Tinelli C, Maggi P, et al. Arterial stiffness evaluation in HIV-positive patients: a multicenter matched control study. AJR Am J Roentgenol 2011; 197:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voelker R. Stroke increase reported in HIV patients. JAMA 2011; 305:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 2011; 76:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janjua SA, Staziaki PV, Szilveszter B, et al. Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. Circ Cardiovasc Imaging 2017; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Ascenzo F, Quadri G, Cerrato E, et al. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. J Cardiovasc Med (Hagerstown) 2015; 16:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinsch N, Esser S, Gelbrich G, et al. Valvular manifestations of human immunodeficiency virus infection--results from the prospective, multicenter HIV-HEART study. J Cardiovasc Med (Hagerstown) 2013; 14:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cicalini S, Forcina G, De Rosa FG. Infective endocarditis in patients with human immunodeficiency virus infection. J Infect 2001; 42:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gebo KA, Burkey MD, Lucas GM, et al. Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr 2006; 43:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prendergast BD. HIV and cardiovascular medicine. Heart 2003; 89:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasudev R, Shah P, Bikkina M, Shamoon F. Infective endocarditis in HIV. Int J Cardiol 2016; 214:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuno JP, Johnson JK, Schweizer ML, et al. Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study. BMC Infect Dis 2011; 11:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miró JM, del Río A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am 2002; 16:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cecchi E, Imazio M, Tidu M, et al. Infective endocarditis in drug addicts: role of HIV infection and the diagnostic accuracy of Duke criteria. J Cardiovasc Med (Hagerstown) 2007; 8:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polanco A, Itagaki S, Chiang Y, Chikwe J. Changing prevalence, profile, and outcomes of patients with HIV undergoing cardiac surgery in the United States. Am Heart J 2014; 167:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaqa AY, Shaaban H, DeBari VA, et al. Viral load and CD4+ cell count as risk factors for prolonged QT interval in HIV-infected subjects: a cohort-nested case-control study in an outpatient population. Cardiology 2010; 117:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gili S, Mancone M, Ballocca F, et al. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. J Cardiovasc Med (Hagerstown) 2017; 18:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997; 20:2810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995; 5:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai YL, Liu HB, Sun B, et al. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs. J Mol Cell Cardiol 2011; 51:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno T, Pérez I, Isasti G, et al. Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013; 29:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenhauer MD, Eliasson AH, Taylor AJ, et al. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 1994; 105:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh M, Arora R, Jawad E. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications. Am J Ther 2010; 17:e193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann Pharmacother 2011; 45:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu JC, Li Y, Marcus GM, et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 2013; 61:2288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West TA, Perram J, Holloway CJ. Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review. Curr Opin HIV AIDS 2017; 12:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chau KH, Scherzer R, Grunfeld C, et al. CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation. J Acquir Immune Defic Syndr 2017; 76:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Sharma S, Simpson DM, Morgello S. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol 2013; 19:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntosh RC. A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy. Clin Auton Res 2016; 26:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntosh RC, Lobo JD, Hurwitz BE. Current assessment of heart rate variability and QTc interval length in HIV/AIDS. Curr Opin HIV AIDS 2017; 12:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow DC, Wood R, Choi J, et al. Cardiovagal autonomic function in HIV-infected patients with unsuppressed HIV viremia. HIV Clin Trials 2011; 12:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow D, Kocher M, Shikuma C, et al. Effects of antiretroviral therapy on autonomic function in early HIV infection: a preliminary report. Int J Med Sci 2012; 9:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Sharma SK. Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity. AIDS Patient Care STDS 2013; 27:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng ZH, Moffatt E, Kim A, et al. Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV. N Engl J Med 2021; 384:2306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freiberg MS, Duncan MS, Alcorn C, et al. HIV Infection and the Risk of World Health Organization-Defined Sudden Cardiac Death. J Am Heart Assoc 2021; 10:e021268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chyu KY, Birnbaum Y, Naqvi T, et al. Echocardiographic detection of Kaposi's sarcoma causing cardiac tamponade in a patient with acquired immunodeficiency syndrome. Clin Cardiol 1998; 21:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush LM, Urrutia JG, Rodriguez EA, Perez MT. AIDS-Associated Cardiac Lymphoma-A Review: Apropos a Case Report. J Int Assoc Provid AIDS Care 2015; 14:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong EJ, Bhave P, Wong D, et al. Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J 2010; 37:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llitjos JF, Redheuil A, Puymirat E, et al. AIDS-related primary cardiac lymphoma with right-sided heart failure and high-grade AV block: insights from magnetic resonance imaging. Ann Cardiol Angeiol (Paris) 2014; 63:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vivekanandarajah A, Bhatt VR, Krishnarasa B, et al. Right upper quadrant pain and mass in a 41-year-old previously healthy man: a presenting feature of HIV-associated extranodal diffuse large B cell lymphoma with cardiac involvement. BMJ Case Rep 2012; 2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little RF, Gutierrez M, Jaffe ES, et al. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA 2001; 285:1880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelsey RC, Saker A, Morgan M. Cardiac lymphoma in a patient with AIDS. Ann Intern Med 1991; 115:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vishnu P, Aboulafia DM. AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy. Adv Hematol 2012; 2012:485943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Bohlius J, Schmidlin K, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23:2029.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3699 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11014331" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cardiomyopathy in AIDS: a pathophysiological perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28057254" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : HIV and Nonischemic Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26251085" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23369416" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : HIV and coronary heart disease: time for a better understanding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22577211" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Immunologic basis of cardiovascular disease in HIV-infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25459601" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20436855" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21868823" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Complications of HIV disease and antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27730474" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cardiovascular Complications of HIV in Endemic Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17460226" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Class of antiretroviral drugs and the risk of myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11762981" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Epidemiology of cardiovascular involvement in HIV disease and AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20689417" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cardiovascular complications of AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21663841" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The metabolic syndrome in HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21088284" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Trends in Diseases Reported on US Death Certificates That Mentioned HIV Infection, 1996-2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25042234" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24798779" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cardiovascular disease in patients with chronic human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28384660" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29482027" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21280474" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Echocardiographic profile of ART naïve human immunodeficiency virus (HIV) infected patients in a tertiary care hospital in Kolkata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22048682" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2530606" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : AIDS: cardiac findings from 115 autopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3351145" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9718123" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753856" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pathology of the heart in acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23817574" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775037" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prevalence of myocarditis and cardiotropic virus infection in Africans with HIV-associated cardiomyopathy, idiopathic dilated cardiomyopathy and heart transplant recipients: a pilot study: cardiovascular topic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26885518" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21217185" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18394461" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19933410" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impact of HIV infection on diastolic function and left ventricular mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739268" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24569532" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23335603" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17266564" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20329440" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26951603" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cardiac Magnetic Resonance Reveals Signs of Subclinical Myocardial Inflammation in Asymptomatic HIV-Infected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26951605" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : HIV-1-Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial Edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7819934" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Heart muscle disease related to HIV infection: prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482143" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8465788" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9770555" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16781213" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cardiovascular disease in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24778120" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28057253" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : HIV and Ischemic Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26164680" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The Broad Spectrum of HIV-Related Cardiovascular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23543004" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3662282" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2829676" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Human immunodeficiency virus, coxsackievirus, and cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2990378" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104517" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cardiac manifestations of HIV infection: an African perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8217449" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7984082" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2178126" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2191195" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Human immunodeficiency virus type 1 antigen detection in endomyocardial biopsy: an immunomorphological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2235989" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Identification of human immunodeficiency virus in the heart of a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15371627" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : HIV-1 induces cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2371952" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Infection of the heart by the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1746436" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Macrophages not cardiomyocytes are the reservoir for lentivirus in SIV cardiomyopathy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3414726" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3177405" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Recombinant alpha 2 interferon-related cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17336407" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cytokines in HIV-associated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468523" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12379743" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12106815" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18222550" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Diffuse-regressive alterations and apoptosis of myocytes: possible causes of myocardial dysfunction in HIV-related cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18990327" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Immune reconstitution inflammatory syndrome and human immunodeficiency virus-associated myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8358862" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Immunopathogenesis of HIV-1-associated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12848988" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : HIV and autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12738029" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Heart disease, methamphetamine and AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18458095" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Methamphetamine enhances HIV infection of macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3499072" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Torsade de pointes during administration of pentamidine isethionate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733387" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10701688" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7608800" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1865554" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10068328" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Dilated cardiomyopathy in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26164679" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838245" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Excellent outcomes of cardiac surgery in patients infected with HIV in the current era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26523614" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15194840" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23608879" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22027640" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pericardial effusion of HIV-infected patients ? Results of a prospective multicenter cohort study in the era of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2926051" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1464334" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Heart involvement in AIDS: a prospective study during various stages of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8017317" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pericardial effusion and pericardiocentesis in human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7586308" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pericardial effusion in AIDS. Incidence and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9458682" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24126882" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : HIV and the heart: the impact of antiretroviral therapy: a global perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23680889" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Recent advances in HIV-associated cardiovascular diseases in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1516433" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : HIV-associated pericardial effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10047635" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24254192" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Myopericarditis in tuberculous pericardial effusion: prevalence, predictors and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25175954" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa: causes and perioperative outcomes in the HIV era (1990-2012).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7781340" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The role of the 'pericardial window' in AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9583822" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Pericardial effusion and AIDS: benefits of surgical drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9432393" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Tuberculous pericardial effusion: a prospective clinical study in a low-resource setting--Blantyre, Malawi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17274459" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Constrictive pericarditis of tuberculous etiology in the HIV-positive patient: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12934767" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Cardiac tamponade in patients with human immunodeficiency virus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22427006" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Tuberculous pericarditis with and without HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15962545" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Epidemiology of pericardial effusions at a large academic hospital in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3351140" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Tuberculous pericarditis: ten year experience with a prospective protocol for diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994147" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7718831" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Tuberculous pericarditis in Tanzanian patients with and without HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1826690" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1898769" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17976506" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : A modern approach to tuberculous pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15120056" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18427200" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20545962" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17932378" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20522575" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11035689" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : HIV-Related pulmonary hypertension: analytic review of 131 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16218798" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17413763" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Venous and arterial thrombosis in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21869916" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : HIV-Associated Venous Thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21114396" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29102088" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997-2013): A nationwide population-based study in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10716509" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11450780" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11445013" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : AIDS and thrombosis: retrospective study of 131 HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20825798" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Venous thromboembolic disease in the HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15006592" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486847" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15869040" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Is chronic HIV infection associated with venous thrombotic disease? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18197123" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Venous thromboembolism in patients with HIV/AIDS: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18783326" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20978394" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Biomarkers and HIV-associated cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24759134" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Coagulation and morbidity in treated HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19828697" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23507662" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19035778" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21448646" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Serum concentrations of antiphospholipid and anticardiolipin antibodies are higher in HIV-infected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18451311" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11177584" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : HIV and thrombosis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14653442" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Acquired protein C and protein S deficiency in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20104124" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : HIV infection: an independent risk factor of peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25182245" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The Prevalence of Peripheral Arterial Disease in HIV Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230043" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : High prevalence of peripheral arterial disease in HIV-infected persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134993" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : The role of postexercise measurements in the diagnosis of peripheral arterial disease in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29535090" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156993" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Low prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22021523" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Arterial stiffness evaluation in HIV-positive patients: a multicenter matched control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21304075" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Stroke increase reported in HIV patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21248273" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Increasing incidence of ischemic stroke in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29021257" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24979113" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335884" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Valvular manifestations of human immunodeficiency virus infection--results from the prospective, multicenter HIV-HEART study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11545570" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Infective endocarditis in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17099314" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12807864" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : HIV and cardiovascular medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27070995" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Infective endocarditis in HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22040268" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12092473" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Infective endocarditis in intravenous drug abusers and HIV-1 infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17312433" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Infective endocarditis in drug addicts: role of HIV infection and the diagnostic accuracy of Duke criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24576521" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Changing prevalence, profile, and outcomes of patients with HIV undergoing cardiac surgery in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20962525" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Viral load and CD4+ cell count as risk factors for prolonged QT interval in HIV-infected subjects: a cohort-nested case-control study in an outpatient population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27635938" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9392812" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Long QTc and torsades de pointes in human immunodeficiency virus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7780290" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21820442" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23638650" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8306734" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636247" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15721475" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Blockade of HERG channels by HIV protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21150558" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22128044" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Protease inhibitor-associated QT interval prolongation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595409" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Sudden cardiac death in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23563125" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28799998" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28797024" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23580249" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27395409" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28984702" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Current assessment of heart rate variability and QTc interval length in HIV/AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21684854" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Cardiovagal autonomic function in HIV-infected patients with unsuppressed HIV viremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22859899" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Effects of antiretroviral therapy on autonomic function in early HIV infection: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032624" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34133860" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34493058" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : HIV Infection and the Risk of World Health Organization-Defined Sudden Cardiac Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891072" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9491957" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Echocardiographic detection of Kaposi's sarcoma causing cardiac tamponade in a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24482102" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : AIDS-Associated Cardiac Lymphoma-A Review: Apropos a Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20844622" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Left ventricular rupture due to HIV-associated T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23830566" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : AIDS-related primary cardiac lymphoma with right-sided heart failure and high-grade AV block: insights from magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22605006" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Right upper quadrant pain and mass in a 41-year-old previously healthy man: a presenting feature of HIV-associated extranodal diffuse large B cell lymphoma with cardiac involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11308402" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863027" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Cardiac lymphoma in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22400030" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19531926" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
